** Shares of Emergent BioSolutions EBS.N fall 12.5% to $5.98 in extended trading, the lowest since September
** Company reported a decline in its fourth-quarter revenue, which stood at $194.7 million, down from $276.6 million a year ago
** On an adjusted basis, company reported EPS of 5 cents, vs a loss of 77 cents previous year
** Company is moving forward with turnaround activities, a critical phase in its multi-year transformation plan - EBS
** Company's shares up 298.3% in 2024
(Reporting by Kritika Lamba in Bengaluru)
((Kritika.Lamba@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.